Search for content, post, videos

Takeda and Lundbeck announce FDA approval of Brintellix

Takeda Pharmaceutical Company and H. Lundbeck A/S jointly have announced that the U.S. Food and Drug Administration (FDA) has approved Brintellix (vortioxetine) for the treatment of adults with major depressive disorder (MDD).

“MDD is a multifaceted disorder that encompasses emotional, physical and cognitive symptoms that may make it challenging to treat,” said Michael Thase, M.D., professor of Psychiatry at the Perelman School of Medicine at the University of Pennsylvania. “Because patients respond to treatments differently, it is important to have additional new options available to help address the overall symptoms of major depression.”

 

The efficacy and safety of Brintellix were established across a comprehensive global clinical trial program, including six positive 6-8 week short-term studies – one of which was a dedicated study in the elderly– that demonstrated statistically significant improvements in overall symptoms of depression. The primary efficacy measure was the mean change from baseline to endpoint in the Hamilton Depression Scale (HAMD-24) total score in two short-term studies, including the elderly study, and the Montgomery-Asberg Depression Rating Scale (MADRS) total score in the other studies.

 

In addition, the clinical trial program included a positive 24-64 week long-term maintenance study in which Brintellix treatment resulted in a statistically significant longer time to recurrence of depressive episodes (defined as a MADRS total score > 22 or as judged by the investigator) compared to placebo. Studies evaluated for safety included more than 4,700 patients aged 18 to 88 years. It is expected that Brintellix will be available to patients by year end 2013.

 

“There are very few new antidepressant drugs currently in development even though so many patients still struggle with depression. We are excited about the approval of Brintellix and being able to offer a new option for patients,” said Anders Gersel Pedersen, executive vice president and head, Research and Development at Lundbeck. “This approval continues our six-decade history of innovation in research and 89341treatments for brain disorders, and underscores the commitment of the Takeda and Lundbeck partnership to bring forward new treatments for depression.”

Leave a Reply

Your email address will not be published. Required fields are marked *

2 × 4 =